Assembly Biosciences Says Assembly Bio Eligible For Up To $280M In Milestones And Royalties Outside U.S.; GS-1179 Expected To Advance Into Phase 2 Trial For Genital Herpes By End Of 2026; Assembly Bio Expects Cash Runway Into 2029

Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its

Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes

Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.

Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties

Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid tumor-associated

Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens

- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization